AstraZeneca PLC ADR
AZN: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$69.00 | Gfyp | Mtynfbfj |
AstraZeneca Holds a Strong Portfolio and Pipeline That Support Solid Long-Term Growth
Business Strategy and Outlook
AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The strong replenishment of new drugs sets up solid long-term growth.